Keytruda and Peripheral coldness - a phase IV clinical study of FDA data

Summary:

Peripheral coldness is reported as a side effect among people who take Keytruda (pembrolizumab), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Zometa, and have Osteoporosis.

The phase IV clinical study analyzes which people have Peripheral coldness when taking Keytruda. It is created by eHealthMe based on reports of 57,304 people who have side effects when taking Keytruda from the FDA, and is updated regularly.

What is Keytruda?

Keytruda has active ingredients of pembrolizumab. It is often used in renal cell carcinoma. eHealthMe is studying from 57,404 Keytruda users. Check the latest studies of Keytruda.

What is Peripheral coldness?

Peripheral coldness is found to be associated with 1,105 drugs and 1,150 conditions by eHealthMe. Check the latest studies of Peripheral coldness.

On Mar, 17, 2026

57,304 people reported to have side effects when taking Keytruda.
Among them, 12 people (0.02%) have Peripheral coldness.

Could Keytruda cause Peripheral coldness?

Among these 12 people:

How long have people been on Keytruda when they have Peripheral coldness? *

What is the gender of people who have Peripheral coldness when taking Keytruda? *

female: 18.18 %
male: 81.82 %

What is the age of people who have Peripheral coldness when taking Keytruda? *

What are other drugs people take besides Keytruda? *

What are other side effects people have besides Peripheral coldness? *

Fatigue (feeling of tiredness): 7 people, 58.33%
Pain In Extremity: 5 people, 41.67%
Malignant Neoplasm Progression (cancer tumour came back): 5 people, 41.67%
Weight Decreased: 4 people, 33.33%
Diarrhea: 4 people, 33.33%
Back Pain: 4 people, 33.33%
Muscle Aches (muscle pain): 4 people, 33.33%
Nausea (feeling of having an urge to vomit): 4 people, 33.33%
Fever: 4 people, 33.33%
Constipation: 4 people, 33.33%

What are the existing conditions these people have? *

Osteoporosis (bones weak and more likely to break): 3 people, 25.00%
Salivary Gland Atrophy (wasting of salivary gland): 2 people, 16.67%
Bone Density Decreased: 2 people, 16.67%
Bladder Transitional Cell Carcinoma (types of bladder cancer): 2 people, 16.67%
Renal Cancer Stage Iv (the tumour has spread to areas beyond gerota's fascia and extends into the adrenal gland on the same side of the body as the tumour, possibly to lymph nodes, but not to other parts of the body): 1 person, 8.33%
Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 1 person, 8.33%
Malignant Melanoma (skin cancer rises from melancytes): 1 person, 8.33%
Lung Neoplasm Malignant (cancer tumour of lung): 1 person, 8.33%
Lung Cancer - Non-Small Cell (lung cancer): 1 person, 8.33%
Hypersensitivity: 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Keytruda and have Peripheral coldness?

- Check whether Peripheral coldness is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Keytruda:

Keytruda (57,404 reports)

Browse all side effects of Keytruda:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Peripheral coldness:

Peripheral coldness (1,105 drugs)

Browse all the conditions that are associated with Peripheral coldness:

Peripheral coldness (1,150 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on pembrolizumab (the active ingredients of Keytruda) and Keytruda (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.